Related Experiment Videos
Multiple myeloma following essential thrombocythemia
F Cobo1, F Cervantes, C Martinez
1Department of Medicine, University of Barcelona, Spain.
Abstract:
The association of essential thrombocythemia (ET) and multiple myeloma (MM) is exceedingly rare, with only four such cases reported in the literature until now. In this paper, a patient is reported who developed IgA-lambda MM more than five years after the diagnosis of ET, for which she had received alpha interferon and radioactive phosphor (32P). She died shortly afterwards despite melphalan and prednisone therapy. In four of the five patients in whom the above association has been reported, including the present one, MM appeared some time after ET was initially recognized, with three of them having received alkylating drugs as their treatment for ET. MM was heterogeneous with respect to the M--component type and the clinical course. The possible etiological & pathogenetic link between both these entities is discussed.
Insights
Essential thrombocythemia (ET) and multiple myeloma (MM) co-occurrence is rare. This report details a patient with ET who developed IgA-lambda MM, highlighting potential links and treatment considerations for these myeloproliferative and plasma cell neoplasms.
Area of Science:
- Hematology
- Oncology
Background:
- Essential thrombocythemia (ET) is a myeloproliferative neoplasm.
- Multiple myeloma (MM) is a plasma cell malignancy.
- The co-occurrence of ET and MM is exceptionally rare in medical literature.